Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 14, 2017

View Archived Issues

Molecular Partners updates pipeline progress

Novel antibody against TGF-beta1 shows efficacy without cardiotoxicity in fibrosis model

TP-0469711 demonstrates promising activity as a new therapeutic for hyperphosphatemia

EMA grants positive opinion for Ocrevus as treatment for patients with RMS or PPMS

Homology Medicines enters R&D collaboration with Novartis

EMA recommends Prevymis for marketing authorization

Theravance Biopharma and Mylan submit NDA in U.S. for revefenacin

Shire's Adynovi receives positive opinion in E.U.

IDX-1197 demonstrates efficacy in models of ovarian cancer

EMA committee backs approval of Jorveza as treatment for eosinophilic esophagitis

EMA confirms further restrictions on use of Zinbryta

QS-1189 inhibits tumor growth in preclinical cancer models

EMA grants orphan drug designation to Debio-1347

Rodin Therapeutics awarded grant from Michael J. Fox Foundation

Phase II data presented for MEDI-6012 in patients with coronary heart disease

PRD-125: a potent SOAT2 inhibitor ameliorates atherosclerosis in rabbits

EMA grants accelerated assessment to patisiran for hereditary ATTR amyloidosis

Akcea initiates phase II program with AKCEA-ANGPTL3-LRx in rare hyperlipidemias

OncBioMune reports new data from phase I ProscaVax study

Positive interim results for phase I trial of ISC-hpNSC in Parkinson's disease

Phase I results reported for Bristol-Myers Squibb candidate for autoimmune diseases

FDA approves digital medicine system Abilify Mycite

Spero Therapeutics identifies novel antibiotic potentiators

Shanghai Hansoh Biomedical, Jiangsu Hansoh Pharmaceutical Group patent IDO-1/TDO inhibitors

Merck & Co. and IOmet Pharma discover novel IDO-1/TDO inhibitors

Dana-Farber Cancer Institute presents anti-CDK9 and CDK8 proteolysis targeting chimera compounds

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 31, 2026.
Emerging therapeutic strategies for Parkinson’s at ADPD 2026
BioWorld
Parkinson’s disease (PD) involves the progressive loss of dopaminergic neurons, particularly in the substantia nigra. This neurodegeneration is linked to the...
With improved technologies, biomarkers, failed drugs may come into their own
BioWorld
At BioEurope Spring 2026, pharma representatives and investors shared their thoughts about current and future landscapes of different disease areas, and on how to...
Small-molecule TREM2 agonist advances to treat Alzheimer’s
BioWorld Science
Microglia play a central role in the neuroinflammation associated with Alzheimer’s disease (AD). These cells act as the brain’s immune system and respond to...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 31, 2026